Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.

about

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.

Item

http://www.wikidata.org/entity/Q55345383

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@en

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@nl

type

Item

label

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@en

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@nl

prefLabel

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@en

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@nl

P1476

Chronic myeloid leukemia patie ...... titudes: a multicenter survey.

@en

P2093

Bingbing Wen

http://www.w3.org/2001/XMLSchema#string

Chuanqing Tu

http://www.w3.org/2001/XMLSchema#string

Jin Lou

http://www.w3.org/2001/XMLSchema#string

Junjie Huang

http://www.w3.org/2001/XMLSchema#string

Wangxiang Huang

http://www.w3.org/2001/XMLSchema#string

Xin Du

http://www.w3.org/2001/XMLSchema#string

Zhimin Zhai

http://www.w3.org/2001/XMLSchema#string

P2860

The concept of treatment-free remission in chronic myeloid leukemia

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

P304

1025-1032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PPA.S163393

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zitong Wang

P577

2018-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29942119

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

6007199

http://www.w3.org/2001/XMLSchema#string